Earnings summaries and quarterly performance for CRISPR Therapeutics.
Executive leadership at CRISPR Therapeutics.
Board of directors at CRISPR Therapeutics.
AB
Ali Behbahani
Detailed
Director
BM
Briggs Morrison
Detailed
Director
CR
Christian Rommel
Detailed
Director
DT
Douglas Treco
Detailed
Lead Independent Director
HE
H. Edward Fleming
Detailed
Director
JG
John Greene
Detailed
Director
KH
Katherine High
Detailed
Director
MF
Maria Fardis
Detailed
Director
SM
Sandesh Mahatme
Detailed
Director
SG
Simeon George
Detailed
Director
Research analysts covering CRISPR Therapeutics.
Recent press releases and 8-K filings for CRSP.
CRISPR Therapeutics Discusses ZugoCell Progress in Oncology and Autoimmune Diseases and Future Platforms
CRSP
New Projects/Investments
- CRISPR Therapeutics is advancing ZugoCell (CTX112), an allogeneic CAR-T therapy, across oncology and autoimmune diseases, aiming for autologous-like efficacy with improved safety and scalability.
- In oncology, ZugoCell has demonstrated almost 70% complete response (CR) rates and is being investigated in combination with pirtobrutinib for enhanced durability in third-line plus relapsed refractory patients.
- For autoimmune indications, ZugoCell is rapidly enrolling patients, with early data in Systemic Lupus Erythematosus (SLE) showing zero disease activity and complete remission in patients up to 9 months off therapy.
- The company anticipates pricing its allogeneic CAR-T therapies in the $200,000 range or slightly lower, significantly below current autologous CAR-T prices, to expand patient access.
Feb 18, 2026, 3:45 PM
CRISPR Therapeutics Discusses ZugoCell Development and Strategic Outlook
CRSP
New Projects/Investments
- CRISPR Therapeutics is advancing ZugoCell (CTX112), an allogeneic CAR-T therapy with advanced edits for enhanced potency and persistence, targeting both autoimmune diseases and oncology.
- In autoimmune indications, ZugoCell has demonstrated promising early results, achieving zero disease activity in two Systemic Lupus Erythematosus (SLE) patients, with one patient maintaining remission for 9 months off therapy. The company is expanding trials to include ITP and WAIHA, with more data expected in the second half of 2026.
- For oncology, ZugoCell showed an initial Complete Response (CR) rate of almost 70% in DLBCL, and CRISPR is exploring a combination with the BTK inhibitor pirtobrutinib to improve durability, with a study ongoing in third-line plus patients.
- CRISPR plans to price its allogeneic CAR-Ts in the $200,000 range or lower in Western markets, significantly below the $350,000-$400,000 for autologous CAR-Ts in oncology and $700,000-$800,000 projected for autoimmune, aiming to increase patient access.
Feb 18, 2026, 3:45 PM
CRISPR Therapeutics Discusses Zugo-cel Development, Pricing Strategy, and In Vivo CAR-T Platforms
CRSP
New Projects/Investments
Product Launch
Guidance Update
- CRISPR Therapeutics is advancing zugo-cel, an allogeneic CAR-T therapy, in both autoimmune and oncology indications, with early data showing zero disease activity in two SLE patients and a 70% complete response rate in DLBCL.
- The company is partnering with Lilly to combine zugo-cel with pirtobrutinib to enhance durability and efficacy in oncology, and anticipates regulatory discussions by the end of 2026 to determine the path forward for both autoimmune and oncology programs.
- CRISPR plans to price zugo-cel around $200,000 or lower, aiming to significantly increase market access compared to autologous CAR-T therapies, which are priced much higher.
- The company is also developing in vivo CAR-T platforms using LNP-mediated delivery for transient (autoimmune) and permanent (oncology) applications.
Feb 18, 2026, 3:45 PM
CRISPR Therapeutics Reports Q4 and Full Year 2025 Financial Results and Business Updates
CRSP
Earnings
New Projects/Investments
Revenue Acceleration/Inflection
- CRISPR Therapeutics reported CASGEVY revenue of $54 million for the fourth quarter of 2025 and $116 million for the full year 2025, with 64 patients receiving infusions during the year, including 30 in the fourth quarter.
- The company's cash, cash equivalents, and marketable securities totaled $1,975.8 million as of December 31, 2025.
- The net loss for the fourth quarter of 2025 was $130.6 million, compared to a net loss of $37.3 million for the fourth quarter of 2024.
- The company is advancing multiple clinical programs, including zugo-cel in autoimmune disease and immuno-oncology, and expects to initiate clinical trials for CTX340 in the first half of 2026 and CTX460 in mid-2026.
Feb 12, 2026, 9:35 PM
CRISPR Therapeutics Reports Q4 and Full Year 2025 Financial Results and Business Updates
CRSP
Earnings
Product Launch
New Projects/Investments
- CRISPR Therapeutics reported CASGEVY revenue of $54 million for the fourth quarter of 2025 and $116 million for the full year 2025, with 64 patients receiving infusions during the year.
- The company's cash, cash equivalents, and marketable securities totaled $1,975.8 million as of December 31, 2025.
- A net loss of $130.6 million was reported for the fourth quarter of 2025, and a net loss of $581.6 million for the full year 2025.
- The company anticipates global regulatory submissions for CASGEVY in pediatric patients in the first half of 2026 and expects to initiate clinical trials for CTX460 in mid-2026 and CTX340 in the first half of 2026.
Feb 12, 2026, 9:30 PM
CRISPR Therapeutics Provides Pipeline and Commercialization Update at J.P. Morgan Healthcare Conference
CRSP
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- CRISPR Therapeutics' gene-editing therapy, Casgevy, achieved over $100 million in revenue and is projected for strong momentum in 2024 and 2025, with ongoing expansion into pediatric populations.
- The in vivo gene editing platform showed promising results with CTX310 for hypercholesterolemia, demonstrating a 50% reduction in LDL cholesterol and a 55% reduction in triglycerides at the highest dose, identified as a multi-billion dollar opportunity.
- Key clinical pipeline assets, CTX611 (siRNA for anticoagulation) and CTX112 (allogeneic CAR-T), are advancing, with CTX611 expecting top-line Phase 2 data by the end of 2026 and CTX112 showing a 70% complete response rate in oncology and sustained remission in autoimmune patients.
- The company views 2026 as a "stepping stone pivotal year" for determining regulatory paths and pivotal trial designs for its advanced clinical assets, while also developing preclinical programs like A1AT and CTX340 (hypertension) as future value drivers.
- CRISPR Therapeutics anticipates that its gene editing procedures, including cardiovascular programs and allogeneic CAR-Ts, could ultimately reduce healthcare costs, with some potentially priced below $100,000.
Jan 12, 2026, 4:15 PM
CRISPR Therapeutics Provides Updates on Casgevy Commercialization and Pipeline Progress at J.P. Morgan Healthcare Conference
CRSP
Product Launch
New Projects/Investments
Guidance Update
- CRISPR Therapeutics reported that Casgevy, an approved product for hemoglobinopathies, has achieved over $100 million in revenue and is showing strong commercial momentum, with plans to expand the addressable patient population through pediatric data and gentler conditioning agents.
- The company presented transformative data for CTX310 in hypercholesterolemia, showing a 50% reduction in LDL cholesterol and a 55% reduction in triglycerides at the highest dose, highlighting its potential as a multi-billion dollar opportunity.
- Significant progress was noted across its in vivo gene editing platform, including CTX320/321 for Lp(a), CTX340 for hypertension entering the clinic soon, and a best-in-class A1AT program also expected to advance to clinical trials.
- CRISPR Therapeutics' CAR-T platform, particularly CTX112, demonstrated encouraging response rates with a 70% CR rate in oncology (DLBCL) and sustained drug-free remission in autoimmune settings (SLE) for up to nine months, positioning it as a potent allogeneic therapy.
- The company also highlighted its siRNA platform, with CTX611 (targeting Factor XI) in a Phase 2 trial, with top-line data anticipated in the second half of 2026, addressing a multi-billion dollar anticoagulation market.
Jan 12, 2026, 4:15 PM
CRISPR Therapeutics Provides Updates on Casgevy Commercialization and Pipeline Progress
CRSP
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- CRISPR Therapeutics' approved product, Casgevy, has achieved over $100 million in revenue and shows strong momentum with a 3x increase in patient initiations and cell collections between 2024 and 2025, indicating multi-billion dollar revenue potential.
- The company reported transformative Phase 1 data for CTX310 (hypercholesterolemia) in November 2025, demonstrating a 50% reduction in LDL cholesterol and a 55% reduction in triglycerides at the highest dose, positioning it as a potential multi-billion dollar opportunity.
- CRISPR is advancing multiple pipeline assets, including CTX112 (CAR-T for oncology and autoimmune diseases) with encouraging response rates reported in December 2025, and CTX611 (siRNA for anticoagulation) with Phase 2 top-line data expected in the second half of 2026, both targeting significant markets.
- For 2026, the company's strategic focus includes commercializing Casgevy, progressing CTX310, CTX611, and CTX112 towards pivotal trials, and moving preclinical assets like A1AT and CTX340 (for hypertension) into clinical development, with potential for partnerships on certain programs.
Jan 12, 2026, 4:15 PM
CRISPR Therapeutics AG Provides Updates on Clinical and Preclinical Programs
CRSP
New Projects/Investments
- CRISPR Therapeutics AG has advanced CTX310 into Phase 1b clinical trials for severe hypertriglyceridemia and refractory hypercholesterolemia, following positive Phase 1 results in 2025.
- The company is progressing zugocabtagene geleucel (zugo-cel) in both autoimmune diseases and hematologic malignancies, reporting positive Phase 1 results in systemic lupus erythematosus (SLE) and a collaboration with Eli Lilly for aggressive B-cell lymphomas.
- CRISPR Therapeutics is also advancing CTX320 and a next-generation LPA program, CTX321, which demonstrates approximately two-fold greater potency in preclinical testing.
- In its regenerative medicine portfolio, the company is transitioning to a next-generation diabetes candidate, CTX213, which has demonstrated compelling preclinical efficacy, informed by promising clinical data from CTX211.
Jan 12, 2026, 1:44 PM
CRISPR Therapeutics Provides Update on Zugo-cel Clinical Development
CRSP
New Projects/Investments
- Zugo-cel, an investigational allogeneic CAR T therapy, demonstrated encouraging preliminary data in autoimmune diseases, with four patients showing deep B-cell depletion and significant clinical improvement, including one systemic lupus erythematosus (SLE) patient achieving DORIS remission through Month 6.
- In relapsed or refractory (R/R) large B-cell lymphoma (LBCL), zugo-cel showed an overall response rate (ORR) of 90% and a complete response rate (CRR) of 70% at the 600 million cell dose, with 67% of patients remaining in complete response after one year.
- CRISPR Therapeutics initiated a new Phase 1 basket trial for zugo-cel in refractory primary immune thrombocytopenic purpura (ITP) and warm autoimmune hemolytic anemia (wAIHA) and established a collaboration with Lilly to evaluate zugo-cel with pirtobrutinib for aggressive B-cell lymphomas.
- Additional updates on zugo-cel across autoimmune disease and hematological malignancies are anticipated in the second half of 2026.
Dec 22, 2025, 1:30 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more